Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2002 Aug 31;325(7362):465.
doi: 10.1136/bmj.325.7362.465.

Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial

Stephen J Falk  1 , David J Girling, Roger J White, Penelope Hopwood, Angela Harvey, Wendi Qian, Richard J Stephens; Medical Research Council Lung Cancer Working Party
Affiliations
Clinical Trial

Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial

Stephen J Falk et al. BMJ. .

Abstract

Objective: To determine whether patients with locally advanced non-small cell lung cancer unsuitable for resection or radical radiotherapy, and with minimal thoracic symptoms, should be given palliative thoracic radiotherapy immediately or as needed to treat symptoms.

Design: Multicentre randomised controlled trial.

Setting: 23 centres in the United Kingdom, Ireland, and South Africa.

Participants: 230 patients with previously untreated, non-small cell lung cancer that is locally too advanced for resection or radical radiotherapy with curative intent, with minimal thoracic symptoms, and with no indication for immediate thoracic radiotherapy.

Interventions: All patients were given supportive treatment and were randomised to receive palliative thoracic radiotherapy either immediately or delayed until needed to treat symptoms. The recommended regimens were 17 Gy in two fractions one week apart or 10 Gy as a single dose.

Main outcome measures: Primary--patients alive and without moderate or severe cough, chest pain, haemoptysis, or dyspnoea six months from randomisation, as recorded by clinicians. Secondary--quality of life, adverse events, survival.

Results: From December 1992 to May 1999, 230 patients were randomised. 104/115 of the patients in the immediate treatment group received thoracic radiotherapy (90 received one of the recommended regimens). In the delayed treatment group, 48/115 (42%) patients received thoracic radiotherapy (29 received one of the recommended regimens); 64 (56%) died without receiving thoracic radiotherapy; the remaining three (3%) were alive at the end of the study without having received the treatment. For patients who received thoracic radiotherapy, the median time to start was 15 days in the immediate treatment group and 125 days in the delayed treatment group. The primary outcome measure was achieved in 28% of the immediate treatment group and 26% of patients from the delayed treatment group (27/97 and 27/103, respectively; absolute difference 1.6%, 95% confidence interval -10.7% to 13.9%). No evidence of a difference was observed between the two treatment groups in terms of activity level, anxiety, depression, and psychological distress, as recorded by the patients. Adverse events were more common in the immediate treatment group. Neither group had a survival advantage (hazard ratio 0.95, 0.73 to 1.24; P=0.71). Median survival was 8.3 months and 7.9 months, and the survival rates were 31% and 29% at 12 months, for the immediate and delayed treatment groups, respectively.

Conclusion: In minimally symptomatic patients with locally advanced non-small cell lung cancer, no persuasive evidence was found to indicate that giving immediate palliative thoracic radiotherapy improves symptom control, quality of life, or survival when compared with delaying until symptoms require treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Trial profile
Figure 2
Figure 2
Percentage of patients surviving after date of randomisation
See this image and copyright information in PMC

Comment in

References

    1. Medical Research Council Lung Cancer Working Party. Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Clin Oncol. 1996;8:167–175. - PubMed
    1. Carroll M, Morgan SA, Yarnold JR, Hill JM, Wright NM. Prospective evaluation of a watch policy in patients with inoperable non-small cell lung cancer. Eur J Cancer Clin Oncol. 1986;22:1353–1356. - PubMed
    1. Phillips TL, Miller RJ. Should asymptomatic patients with inoperable bronchogenic carcinoma receive immediate radiotherapy? Yes. Am Rev Respir Dis. 1978;117:405–410. - PubMed
    1. Cox JD, Komaki R, Byhardt RW. Is immediate chest radiotherapy obligatory for any or all patients with limited-stage non-small cell carcinoma of the lung? Yes. Cancer Treat Reps. 1983;67:327–331. - PubMed
    1. Brashear RE. Should asymptomatic patients with inoperable bronchogenic carcinoma receive immediate radiotherapy? No. Am Rev Respir Dis. 1978;117:411–414. - PubMed

Publication types